SubsidieMeestersDRUG-ELUTING ELECTRICAL IMPLANT TO REPAIR THE SPINAL CORD
DREIMS aims to advance a novel drug-eluting electrical implant for spinal cord repair by refining its design and meeting regulatory standards for human therapeutic use.
Projectdetails
Introduction
In Neurofibres (FET-PROACTIVE, 2017-2021), we accomplished a major therapeutic advance for spinal cord injury (SCI) by combining biomaterials, pharmaceuticals, and electrical stimulation into an innovative implant able to promote the closure of the spinal cord gap, with axonal regrowth and glial cell migration across large lesions in rodent and porcine models of SCI.
Implant Design
In brief, the implant comprised biofunctionalized, conducting polymer-coated carbon microfibres (MFs) that promoted aligned neural cell growth across the lesion, embedded within a drug-eluting hydrogel that filled the tissue defect and reduced fibrosis. These intraspinal elements were complemented with electrodes that provided biphasic electrical stimulation (ES) to the lesion and the perilesional tissue, thus inducing extensive neural regeneration.
Project Development
Building on the initial proof of concept achieved in Neurofibres (TRL 3), DREIMS will mature this novel healthcare technology through TRLs 4-5, becoming close to its approval for use in human therapeutics while creating a business plan to support further exploitation steps.
Intellectual Property and Business Strategy
The inventors of the implant filled a patent application (P202230626) on the mentioned results and recently created a spin-off company (Spinal Cord Technologies, SCT S.L.) to pursue the refinement and validation of a successful clinical and commercial medical product.
Integration of Technologies
DREIMS builds on those results to consolidate the first-in-class drug-eluting electrical implant to repair the spinal cord. The implant will refine and integrate three modules:
- Microfiber/drug-eluting gel bundles (MIBs) from FUHNPAIIN / SCT S.L. (Spain)
- Spinal electrode arrays (SEAs) from ALU-FR/IMTEK (Germany)
- A fully implantable electric pulse generator (IPG) from NEURINNOV (France)
This will form a procedure pack according to the European Medical Device Regulation (MDR) 2017/745.
Regulatory and Market Readiness
Addressing regulatory requirements and business development activities will increase the market readiness of the implant.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.494.542 |
| Totale projectbegroting | € 2.646.417 |
Tijdlijn
| Startdatum | 1-12-2023 |
| Einddatum | 30-11-2026 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- FUNDACION HOSPITAL NACIONAL DE PARAPLEJICOSpenvoerder
- ALBERT-LUDWIGS-UNIVERSITAET FREIBURG
- NEURINNOV
- SPINAL CORD TECHNOLOGIES S.L.
Land(en)
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationSThe NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring. | EIC Transition | € 2.497.750 | 2022 | Details |
Predictive REagent-Antibody Replacement Technology stage 2-TranslationPRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment. | EIC Transition | € 800.000 | 2022 | Details |
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stageDeveloping a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships. | EIC Transition | € 2.499.810 | 2022 | Details |
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationS
The NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring.
Predictive REagent-Antibody Replacement Technology stage 2-Translation
PRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment.
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage
Developing a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Piezo-driven theramesh: A revolutionary multifaceted actuator to repair the injured spinal cordPiezo4Spine aims to create a groundbreaking 3D bioprinted mesh therapy for spinal cord injury that enhances neural repair through targeted mechanotransduction and gene therapy. | EIC Pathfinder | € 3.537.120 | 2023 | Details |
Biodegradable MEMS implants for nerve repairDevelop biodegradable MEMS implants for nerve repair using innovative mechanical stimulation strategies to enhance neural regeneration post-injury. | ERC STG | € 1.672.968 | 2023 | Details |
A Digitally-Enabled Electroconductive Patient-Specific Stimulation Implant for Spinal Cord InjuryThis project aims to develop a patient-specific 3D-printed neuromodulation implant to enhance neuron regrowth and restore function in spinal cord injury patients through targeted electrical stimulation. | ERC POC | € 150.000 | 2025 | Details |
Robotic and Electrical Stimulation Platform for Integral Neuromuscular EnhancementRE-SPINE creates a neuro-robotic platform combining a robotic ankle exoskeleton and spinal stimulation to enhance lower limb rehabilitation and promote motor recovery after neuromuscular injuries. | ERC POC | € 150.000 | 2025 | Details |
Piezo-driven theramesh: A revolutionary multifaceted actuator to repair the injured spinal cord
Piezo4Spine aims to create a groundbreaking 3D bioprinted mesh therapy for spinal cord injury that enhances neural repair through targeted mechanotransduction and gene therapy.
Biodegradable MEMS implants for nerve repair
Develop biodegradable MEMS implants for nerve repair using innovative mechanical stimulation strategies to enhance neural regeneration post-injury.
A Digitally-Enabled Electroconductive Patient-Specific Stimulation Implant for Spinal Cord Injury
This project aims to develop a patient-specific 3D-printed neuromodulation implant to enhance neuron regrowth and restore function in spinal cord injury patients through targeted electrical stimulation.
Robotic and Electrical Stimulation Platform for Integral Neuromuscular Enhancement
RE-SPINE creates a neuro-robotic platform combining a robotic ankle exoskeleton and spinal stimulation to enhance lower limb rehabilitation and promote motor recovery after neuromuscular injuries.